# ENDO-B-GALACTOSIDASE AND CELL SURFACE GLYCOCONJUGATES

> **NIH NIH R01** · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · 1987 · $92,257

## Abstract

Lactosaminoglycan proteins are a group of glycoproteins present in plasma
membranes.  Their carbohydrates often serve as cell surface antigens,
including Ii, ABH and SSEA-1, which change drastically during cellular
differentiation, embryonal development and oncogenesis.

Human embryonal carcinoma cell, PA1, resembles the cells of the
preblastocyst or trophectoderm of the early blastocyst stage of mouse
embryo in many ways.  We have determined that large glycopeptides present
in PA1 cells are branched lactosaminoglycans with novel disialosyl (NeuNAc
alpha2 yields 9 NeuNAc) sequences.  We plan to prepare monoclonal
antibodies against the NeuNAc alpha2 yields 9 NeuNAc structure to study the
distribution of this structure among embryonal cells and tumor cells.  Such
monoclonal antibodies with defined specificity would also be useful
reagents to detect oncodifferentiation antigen and to diagnose tumors.

We plan to elucidate the relationship between lactosaminoglycans and
complex type oligosaccharides, focusing on their core structures,
distribution of lactosaminyl side chains and the occurrence of disialyl
structure.  PA1 lactosaminoglycans are specifically carried by a
glycoprotein (Gp95).  Gp95 will be purified and antibodies specific to Gp95
will be prepared.  We will examine the distribution of Gp95 among various
cell lines by using the antibodies in order to evaluate this glycoprotein
as a protein specific to human embryonal carcinoma cells as well as early
embryonic cells.

We have characterized glycolipids present in PA1 cells and have found that
PA1 cells contain mono- and disialylated glycolipids with blood group type
1 sequence.  We plan to characterize 0-glycosidic carbohydrates so that the
overall structural features of cell surface glycoconjugates on PA1 cells
can be established.

These studies will provide us with structural information on carbohydrate
antigens expressed in teratocarcinoma cells and early stage embryos.  Our
study will ultimately be helpful for understanding the role of cell surface
glycoconjugates in cellular differentiation and oncogenesis.

## Key facts

- **NIH application ID:** 3171743
- **Project number:** 3R01CA034014-04A1S1
- **Recipient organization:** SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- **SAM.gov UEI:** PHMKYKKJLQS1
- **Principal Investigator:** Michiko Fukuda
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $92,257
- **Award type:** 3
- **Project period:** 1983-02-01 → 1989-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171743

## Citation

> US National Institutes of Health, RePORTER application 3171743, ENDO-B-GALACTOSIDASE AND CELL SURFACE GLYCOCONJUGATES (3R01CA034014-04A1S1). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171743. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*